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Abstract
In the human neoplastic cell lines 5637 and HeLa, recombinant CXCL12 elicited, as expected, downstream signals via both
G-protein-dependent and b-arrestin-dependent pathways responsible for inducing a rapid and a late wave, respectively, of
ERK1/2 phosphorylation. In contrast, the structural variant [N33A]CXCL12 triggered no b-arrestin-dependent phosphor-
ylation of ERK1/2, and signaled via G protein-dependent pathways alone. Both CXCL12 and [N33A]CXCL12, however,
generated signals that transinhibited HER1 phosphorylation via intracellular pathways. 1) Prestimulation of CXCR4/HER1-
positive 5637 or HeLa cells with CXCL12 modified the HB-EGF-dependent activation of HER1 by delaying the peak
phosphorylation of tyrosine 1068 or 1173. 2) Prestimulation with the synthetic variant [N33A]CXCL12, while preserving
CXCR4-related chemotaxis and CXCR4 internalization, abolished HER1 phosphorylation. 3) In cells knockdown of b-arrestin
2, CXCL12 induced a full inhibition of HER1 like [N33A]CXCL12 in non-silenced cells. 4) HER1 phosphorylation was restored
as usual by inhibiting PCK, calmodulin or calcineurin, whereas the inhibition of CaMKII had no discernable effect. We
conclude that both recombinant CXCL12 and its structural variant [N33A]CXCL12 may transinhibit HER1 via G-proteins/
calmodulin/calcineurin, but [N33A]CXCL12 does not activate b-arrestin-dependent ERK1/2 phosphorylation and retains a
stronger inhibitory effect. Therefore, we demonstrated that CXCL12 may influence the magnitude and the persistence of
signaling downstream of HER1 in turn involved in the proliferative potential of numerous epithelial cancer. In addition, we
recognized that [N33A]CXCL12 activates preferentially G-protein-dependent pathways and is an inhibitor of HER1.
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Introduction
CXCL12 regulates important hematopoietic functions, induces
cell adhesion and chemotaxis, and coordinates the circulation of
hematopoietic stem cells, lymphocytes and monocytes [1], [2], [3].
Stromal and endothelial cells constitutively express CXCL12 in
bone marrow, lymph nodes, liver, lung and skin [4]. As far as
cancer growth is concerned, CXCL12 may induce mitotic signals,
favor metastatic evolution and contribute to the development of a
microenvironment dominated by M2-polarized, anti-inflammato-
ry, tumor-associated macrophages that support tumor cell survival
[5], [6], [7], [8]. Notably, cancer cells usually express functional
receptors for CXCL12 and some cancers constitutively express
CXCL12 [2], [7], [8].
CXCL12 elicits cellular responses by binding to CXCR4 and
CXCR7, which are seven transmembrane receptors (7TMR) that
activate G-proteins [9]. Though the role of CXCR7 is not fully
understood up to date [10], [11], it is known that downstream of
CXCR4 native CXCL12 activates both G-protein-dependent and
b-arrestin-dependent signaling pathways, which may support
distinct intracellular messages [12], [13], [14]. It seems that
structural variants of either the ligand or the receptor may result in
the dissociated activation of either G-protein- or b-arrestin-
dependent pathways, followed by different cellular responses
[13], [15], [18].
By binding to its receptors, CXCL12 induces another
interesting phenomenon, i.e. the transactivation of the human
EGF receptor 1 (HER1) and other HER family members. Such a
crosstalk is a general function of 7TMR signaling [19], including
CXCR4 [8]. Usually the transactivation occurs in a paracrine
manner. For instance, the ligation of CXCR4 activates membrane
metalloproteinases, which release HER1 ligands such as EGF or
HB-EGF from cell membrane resulting in their binding to HER1
[8], [19], [20], [21]. This induces kinase-dependent autophospho-
rylation of cytoplasmic tail residues on HER1 leading to a
signaling cascade that is involved in the proliferation, morpho-
genesis and differentiation of both normal and neoplastic cells
[22]. HER1 is often expressed by epithelial cancer and plays a role
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growth-inhibitory cytokines and the expression of selective
immunosuppressive cytokines, proangiogenic cytokines, and
chemokines [23].
In HERs/CXCR4 double-positive cells, a transactivation of
HERs along intracytoplasmic pathways is possible and was
described [24]. Indeed, intracytoplasmic transactivation was
shown to be important in breast cancer [25] and myeloma
progression [26]. Here we provide the unexpected evidence
that CXCL12 may transhinibit HER1. Using the bladder
cancer cell line 5637 and the cervical cancer cell line HeLa,
w h i c hi sa ne s t a b l i s h e din vitro model for studying both HER1
and CXCR4 signaling [4], [27], we found that CXCL12 elicits
a calmodulin/calcineurin pathway, thereby delaying the
autophosphorylation peak of HER1. Remarkably, we observed
that the fully active, synthetic mutant [N33A]CXCL12 [28]
was biased for G- protein-dependent pathways failing to
activate b-arrestin-dependent ERK1/2 phosphorylation down-
stream of CXCR4 and could completely, though transiently,
block HER1 phosphorylation.
Materials and Methods
Cells
The 5637 (bladder carcinoma) and HeLa (cervical carcinoma)
human cell lines, purchased from American Type Culture
Collection, were grown in DMEM+10% FCS (Invitrogen,
Carlsbad, CA) until confluence and were subsequently detached
by accutase (Innovative Cell Technologies, San Diego, CA).
Flow cytometry
Cells under basal conditions or following stimulation for
20 minutes with 200 ng/mL CXCL12 (Peprotech, London, UK)
or 25 ng/mL HB-EGF (R&D Systems, Minneapolis, MN) were
detached and incubated with anti-human PE-tagged CXCR4 or
HER1 mAbs, as well as appropriate isotype controls (BD
Pharmingen, San Jose, CA). Cells were analyzed on a FACSCa-
libur (Becton-Dickinson, Mountain View, CA) flow cytometer
running FlowJo 8.8.2 software (Tree Star, Ashland, OR).
HER1 stimulation
Semiconfluent, 24-hour starved cells were incubated in the
presence or absence of 25 ng/mL recombinant human HB-EGF
Figure 1. Receptors involved in the crosstalk between CXCL12 and HER1. 5637 or HeLa cells were cultured alone, or in the presence of
200 ng/mL CXCL12 or 25 ng/mL HB-EGF. After 20 minutes, the cells were collected and evaluated by flow cytometry for the expression of CXCR4 and
HER1. (A) Stimulation with CXCL12 led to downregulation of CXCR4 due to its internalization. (B) Stimulation with HB-EGF induced HER1
internalization. In contrast, no changes in the surface expression of HER1 were detected after stimulation with CXCL12. Thus, CXCL12 binding to
CXCR4 did not transactivate HER1 in these cells via shedding of HER1 ligands. Representative flow cytometry patterns and the means 6SD of 10
experiments are depicted.
doi:10.1371/journal.pone.0034432.g001
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chemically synthesized [N33A]CXCL12 (BD PharMingen, San
Diego, CA). In selected experiments, HeLa cells were prestimu-
lated for 1 minute with either 200 ng/mL recombinant human
CXCL12 (BD PharMingen) or chemically synthesized
[N33A]CXCL12 and subsequently stimulated with 25 ng/mL
HB-EGF. Cell pellets were obtained to perform protein extrac-
tions at different treatment times ranging from 1 to 15 minutes.
Protein extraction
Cell pellets were lysed for 30 minutes in 1 mL of ice-cold cell
extraction buffer (Biosource, Camarillo, CA) that was supple-
mented with a protease inhibitor cocktail (Sigma, St. Louis, MO)
and 1 mM PMSF (Sigma). After centrifugation at 13,000 rpm for
10 minutes at 4uC, aliquots of supernatants were stored at 280uC
until used.
ELISA
Total HER1 and HER1 pY1068 or pY1173, and total ERK1/2
and ERK1/2 pTY185/187 were evaluated in cell protein extracts
by using commercially available ELISA kits (Biosource). The
results were expressed as percentages of phosphorylation at the
specified times after normalization as phosphorylated molecule/
total molecule ratios.
Mass spectrometry
Around 1610
7 cells, either unstimulated or stimulated with
25 ng/mL HB-EGF for 15 minutes, were harvested and under-
went HER1 immunoprecipitation, reduction, alkylation and
tryptic digestion. Ten microliter aliquots of each resulting peptide
mixture were analyzed by LC-MS/MS (liquid chromatography
coupled to an ion trap mass spectrometer) system [29]. Data
handling for the identification of phosphorylated residues was
performed according to the method of Guo et al. [30]. HB-EGF-
induced HER1 phosphorylation at Y992, Y1045, Y1068, Y1086,
Y1148, Y1173 and S1142 was evaluated.
Proliferation of cells
Approximately 2,500 cells/well were seeded in 96-well plates
and allowed to adhere for 24 hours, prior to incubation with
25 ng/mL HB-EGF and/or 200 ng/mL recombinant human
CXCL12 and/or 1 mg/mL cyclosporin A (CsA, Novartis, Origgio,
Italy). After 72 hours, the proliferation of stimulated vs. unstimu-
lated cells was measured by MTT [3-(4, 5-dimethyl-thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] incorporation, as previously
described [31].
siRNA transfection
To silence the expression of b-arrestin 2, 5637 or HeLa cells
were seeded on 12-well plates (1.2610
5) and transfected 72 hours
using HiPerFect Transfection Reagent and siRNA (2 nM, b-
arrestin 2 siRNA no. SI02776928 and AllStars negative control
siRNA – Alexa Fluor 488; Qiagen, Hilden, D) as previously
described [8]. Transfection efficiency (.95%) was determined by
flow cytometry on trypsinized cells. At the end of colture, cells
were starved for 4 hours, prestimulated for 1 minute with 200 ng/
mL recombinant human CXCL12 and then with 25 ng/mL HB-
EGF for 2, 4, 5, 7, 10 or 15 minutes. Cell pellets were obtained to
perform protein extractions and ELISA for total HER1 and
HER1 pY1068 or pY1173 as reported above.
Transduction pathway inhibition
Semiconfluent, 24-hour starved cells were exposed for 30 min-
utes to 5 mM 2-{1-[3-(Amidinothio)propyl]-1H-indol-3-yl}-3-(1-
methylindol-3-yl)maleimide methanesulfona-te salt (Ro-31-8220;
Sigma-Aldrich) or 44 mM N-(4-Aminobutyl)-5-chloro-2-naphtha-
lenesulfonamide hydrochloride (W-13; Sigma-Aldrich),) or 30 mM
1-[N, O–bis-(5-Isoquinolinesulfonyl)–N–methyl-L-tyrosyl]-4-phe-
nylpiperazine (KN-62; Calbiochem, La Jolla, CA) or 1 mg/mL
Cyclosporin A (CsA; Sigma-Aldrich),) – specific inhibitors of PKC,
calmodulin, CaMKII and calcineurin, respectively. HeLa cells
were then treated with 200 ng/mL human recombinant CXCL12
Figure 2. Phosphorylation of HER1 and ERK1/2, and cell
proliferation following treatment with HB-EGF and CXCL12.
(A) 5637 and HeLa cells were stimulated with 25 ng/mL HB-EGF for
20 minutes, and cell lysates were analyzed by mass spectrometry
following trypsin digestion. Y1068 and Y1173, sites of autophosphory-
lation coupled to the activation of Ras, MEK and ERK1/2, were evaluated
in the following experiments with specific phosphotyrosine mAbs. (B)
HB-EGF induced phosphorylation of both HER1 Y1068 and ERK1/2
TY185/187 in 5637 or HeLa cells. In contrast, stimulation with 200 ng/
mL CXCL12 for 20 minutes, which induced phosphoERK1/2, led to no
phosphorylation of HER1. (C) In dose-response experiments, exposures
of CXCL12 ranging from 6 to 400 ng/mL for 20 minutes did not induce
HER1 phosphorylation in either cells. (D) No proliferation was induced
with 200 ng/mL CXCL12. The means 6SD of 10 experiments are
depicted.
doi:10.1371/journal.pone.0034432.g002
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PharMingen) for up to 15 minutes or for 1 minute before
stimulation with 25 ng/mL HB-EGF for up to 15 minutes.
Statistics
Student’s t-test, Mann-Whitney U test and Kruskall-Wallis
ANOVA by ranks were used. Differences were considered
significant for p values ,0.05.
Results
CXCL12 does not transactivate HER1 in 5637 or HeLa cells
Like other epithelial cells, 5637 and HeLa cells co-express
HER1 and CXCR4 under basal conditions (Figure 1A, B). For
stimulation of 7TMRs, such as CXCR4, leads to metalloprotease-
induced shedding of EGF-family ligands, we wondered if
CXCL12, the ligand of CXCR4, could transactivate HER1 in
5637 or HeLa cells. As shown in Figure 1A, stimulation of 5637 or
HeLa cells with 200 ng/mL CXCL12 led to CXCR4 downreg-
ulation, which implies that CXCL12 bound to its receptors and
triggered internalization. In contrast, HER1 was not downregu-
lated following CXCL12 stimulation (Figure 1B). When cells,
however, were stimulated with 25 ng/mL HB-EGF, HER1 was
induced to internalize following ligand binding (Figure 1B).
Because HER1 transactivation via binding of a shedded ligand
would ultimately be indicated by HER1 internalization, we
concluded that CXCL12 did not induce HER1 transactivation
in 5637 or HeLa cells through this mechanism. Another approach
implies evaluating the phosphorylation of HER1 and downstream
of HER1 associated with different stimuli.
HER1 phosphorylation in 5637 and HeLa cells
To demonstrate the full sensitivity of 5637 and HeLa cells to
HER1 stimulation, we assessed the full pattern of HB-EGF-
induced HER1 phosphorylation at tyrosine (Y992, Y1045, Y1068,
Y1086, Y1148, Y1173) and serine (S1142) residues by mass
spectrometry analysis of trypsin-digested peptides. The results are
depicted in Figure 2A. After treatment with 25 ng/mL HB-EGF
for 20 minutes, there was no phosphorylation of Y1045, while the
remaining tyrosine sites showed different degrees of phosphoryla-
Figure 3. CXCL12 regulates HER1 Y1068 and Y1173 phosphorylation via G-proteins. 5637 or HeLa cells were stimulated with 25 ng/mL
HB-EGF or with 200 ng/mL CXCL12 or N33A]CXCL12 alone or followed after 1 minute by 25 ng/mL HB-EGF. HER1 Y1068 or ERK1/2 TY185/187
phosphorylation was evaluated at the indicated time-points by using specific mAbs and was expressed as percentages of phosphorylation at the
specified times after normalization as phosphorylated molecule/total molecule ratios. (A) HER1 phosphorylation at Y1068 in HeLa cells induced by
HB-EGF alone (black) was abolished by prestimulation with [N33A]CXCL12 (blue) and modified by prestimulation with CXCL12 (red): maximum
phosphorylation was reached at 4 minutes, and the plateau after the initial spike was around 50% of the maximum at 10 minutes. No
phosphorylation was induced by CXCL12 alone. (B) Phosphorylation at Y1173 in 5637 cells displayed the same kind of pattern. (C) Prestimulation with
CXCL12 did not modify the mitogenic effect of HB-EGF. (D) Stimulation with CXCL12 induced ERK1/2 phosphorylation (red) resulting from two spikes:
a G-protein-dependent (blue) and a b-arrestin-dependent (red) phosphorylation spike. By using the PKC inhibitor Ro-31 the G-protein-dependent
spike was abolished, whereas the b-arrestin-dependent spike persisted. [N33A]CXCL12 induced only the G-protein-dependent spike (blue), which was
abolished by Ro-31. (E) Ro-31 abolished the effects of prestimulation with CXCL12 or [N33A]CXCL12 at Y1068 in 5637 cells. (F) The same pattern at
Y1173 in HeLa cells. The means 6SD of 10 experiments are depicted.
doi:10.1371/journal.pone.0034432.g003
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ylation status of the HER1 tyrosine 1068 and 1173, two major site
of autophosphorylation related to the activation of Ras, MEK and
ERK1/2. The phosphorylation of tyrosine 1068 (pY1068) and
1173 (pY1173) is followed by downstream ERK1/2 phosphory-
lation at threonine 185 and tyrosine 187 (pTY185/187) [22].
HER1 and ERK1/2 phosphorylation in 5637 and HeLa cells
Then, we analyzed the phosphorylation status of HER1 Y1068
and of ERK1/2 T185 and Y187 following stimulation of 5637 or
HeLa cells with 25 ng/mL HB-EGF or 200 ng/mL CXCL12 for
20 minutes. Figure 2B shows that HB-EGF induced the
phosphorylation of HER1 at Y1068 as well as ERK1/2 at T185
and Y187. By contrast, treatment with CXCL12 phosphorylated
ERK1/2 but did not induce any HER1 phosphorylation. In
addition, treatment with different concentrations of CXCL12 (up
to 400 ng/mL) for different amounts of time (1 up to 20 minutes)
did not phosphorylate HER1 (Figure 2C). Finally, CXCL12 did
not lead to cell proliferation, whereas HB-EGF was a mitogenic
agent (Figure 2D). Thus, CXCL12 did not transactivate HER1 in
5637 or HeLa cells.
CXCL12 and its chemically synthesized mutant
[N33A]CXCL12 regulate HER1 phosphorylation
Figure 3 shows a time-course of HER1 phosphorylation at
Y1068 in HeLa (Figure 3A) and at Y1173 in 5637 (Figure 3B) cells
after three different stimuli: 1) CXCL12 alone or 2) HB-EGF
alone or 3) CXCL12 followed by stimulation with HB-EGF.
Stimulation with CXCL12 alone induced no phosphorylation of
HER1. With HB-EGF alone, HER1 phosphorylation reached a
maximum at 1 minute, followed by partial dephosphorylation and
a plateau at approximately 60% of maximal phosphorylation after
10 minutes. In contrast, cells prestimulated with CXCL12 showed
a different pattern of HB-EGF-dependent HER1 phosphorylation.
Treatment of cells with CXCL12 impacted HER1 phosphoryla-
tion in a typical way: the maximum degree of phosphorylation was
reached later. Following stimulation with CXCL12, maximal
phosphorylation was reached at 4 minutes, and the plateau after
the initial spike was around 50% of the maximum after 10 minutes
(Figure 3A, B). This delay in activation was not merely due to the
more complex mechanistics of transactivation as opposed to direct
stimulation with HB-EGF. Prestimulation with CXCL12 imme-
diately followed by exogenous addition of HB-EGF to the cells led
to the same phosphorylation pattern. Interestingly, the whole
phenomenon was associated with a similar mitogenic effect of HB-
EGF (Figure 3C), which suggested that CXCL12 sent inhibitory
signals to HER1, which were transient in nature. In addition, we
confirmed that the variant [N33A]CXCL12 had the same range
of activity as the recombinant, non-variant form as far as CXCR4
stimulation, chemotactic activity and internalization were con-
cerned [32]. However, prestimulation of the cells with 200 ng/mL
of [N33A]CXCL12 for 1 minute inhibited HB-EGF-dependent
phosphorylation of HER1. Whereas recombinant CXCL12
delayed the phosphorylation of HER1, [N33A]CXCL12 abol-
ished it (Figure 3A, B).
[N33A]CXCL12 acts as a G-protein-biased ligand
Figure 3D shows that downstream of CXCR4 the whole
phosphorylation of ERK1/2 occurs in fact as a consequence of
two different, sequentially ordered phosphorylation activities
translating into two distinct ERK1/2 phosphorylation spikes: a
precocious one that was G-protein-dependent via PKC and a late
one that was b-arrestin-dependent. By using Ro-31, which inhibits
PKC, recombinant CXCL12 induced only a late, b-arrestin-
dependent ERK1/2 phosphorylation spike, but [N33A]CXCL12
induced no ERK1/2 phosphorylation at all. Therefore,
[N33A]CXCL12 did not induce the b-arrestin-dependent phos-
phorylation of ERK1/2, while eliciting the G-protein-dependent
spike. Panels E and F in Figure 3 show also that the inihibition of
G-protein-dependent PKC with Ro-31 abolished the effect on
HER1 phosphorylation at Y1068 and Y1173 induced by either
recombinant or mutated CXCL12 prestimulation. Both the
CXCL12-dependent delay and the [N33A]CXCL12-dependent
full inhibition of HER1 phosphorylation seemed to be a G-
protein-dependent phenomenon mediated via PKC.
Blockade of b-arrestin 2 in 5637 and HeLa cells
If the variant form [N33A]CXCL12 induces full inhibition of
HER1 for lack of b-arrestin activation, then recombinant
CXCL12 should induce a full inhibition of HER1 in cells
knockdown of b-arrestin. Therefore, to further test the transduc-
tion pathways downstream of CXCR4 we established a siRNA
sequence targeted against the CXCR4-associated b-arrestin 2.
This siRNA efficiently blocked b-arrestin in both 5637 and HeLa
cells. Figure 4 shows that, when prestimulated with CXCL12, cells
knockdown of b-arrestin 2 displayed no HB-EGF-dependent
phosphorylation spikes and statistically significant less phosphor-
ylation at HER1 Y1068 or Y1173 than their controls (p,0.05).
Therefore, b-arrestin-silenced cells reacted to CXCL12 the way
non-silenced cells reacted to [N33A]CXCL12, i.e. the prestimula-
tion with CXCL12 resulted in a full inhibition of HB-EGF-
dependent HER1 phosphorylation. These b-arrestin silencing data
complement the ERK1/2 phosphorylation and Ro-31 blocking
Figure 4. Knockdown of b-arrestin 2 protein levels allows for
transinhibition of HER1. 5637 or HeLa cells were transfected with
control siRNA or b-arrestin 2 siRNA, prestimulated for 1 minute with
200 ng/mL CXCL12 and subsequently stimulated with 25 ng/mL HB-
EGF for 2, 4, 5, 7, 10 or 15 minutes. In knockdown cells either Y1068 or
Y1173 phosphorylation was inhibited as opposed to non-silenced cells
at each time observed, as determined by ELISA (p,0.05). This shows
that CXCL12 signaling transinhibits HER1 phosphorylation via G-
protein-pathways in the absence of b-arrestin 2 activation and further
supports that [N33A]CXCL12, which strongly transhinibits HER1, is a G-
protein-biased ligand. The means 6SD out of 4 experiments are shown.
doi:10.1371/journal.pone.0034432.g004
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CXCL12 may send inhibitory signals to HER1 through a G-
protein/PKC dependent pathway when b-arrestin is not activated
and 2) the variant form [N33A]CXCL12 signals preferentially
through G-proteins/PKC (as also suggested by using the Ro-31
inhibitor) and does not activate b-arrestin (as also suggested by the
lack of the late, b-arrestin-dependent ERK1/2 phosphorylation
spike). Finally, the same pattern of inhibition/restoration of HER1
phosphorylation was present in both 5637 and HeLa cells.
CXCL12 transinhibits HER1 via PKC/calmodulin/
calcineurin
There were a number of candidate pathways to mediate the
inhibitory effect induced by both forms of CXCL12 downstream
of G-proteins/PKC. However, it is known that calmodulin can be
activated by any sustained Ca
2+ flux, thus suggesting a mechanism
by which known signaling participants can modulate HER1
signaling. After treatment with CXCL12 or [N33A]CXCL12, we
observed that not only the PKC inhibitor Ro-31 (Figure 3E, F),
but also the calmodulin inhibitor W-13 restored the HER1
phosphorylation pattern induced by HB-EGF alone either in 5637
or HeLa cells (Figure 5A, B). Downstream of calmodulin, the
signal is divergent toward calcineurin and Ca
2+-calmodulin-
dependent protein kinase II (CaMKII). CsA, a specific inhibitor
of calcineurin, prevented the CXCL12 effect and was capable of
restoring the normal pattern of HER1 phosphorylation (Figure 5A,
B). Calcineurin activity was therefore necessary for CXCL12 to
modify the phosphorylation pattern of HER1. Figure 5C depicts
the pattern of HER1 Y1068 and Y1173 phosphorylation at the
plateau in 5637 or HeLa cells. Pretreatment with [N33A]CXCL12
was fully inhibitory at this time, but calmodulin and calcineurin
inhibitors W-13 and CsA, respectively, restored HER1 phosphor-
ylation. CaMKII inhibitor KN-62 did not restore the phosphor-
ylation, and the whole process was independent from CaMKII,
which was not activated by CXCL12 signaling (data not shown).
In conclusion, specific modifications to the primary structure of
CXCL12 may lead to a preferential or biased activation of G-
protein-dependent pathways downstream of CXCR4, activation
of calmodulin and calcineurin, and the complete inhibition of
HER1 autophosphorylation.
Discussion
The current study in 5637 and HeLa cells defines a novel
mechanism of crosstalk between CXCR4 and HER1, whereby
stimulation with recombinant CXCL12 modifies the pattern of
HER1 phosphorylation via G-proteins/calmodulin/calcineurin.
Beside, the study identifies [N33A]CXCL12 as a mutant of
CXCL12 as a G-protein-biased CXCR4 ligand that induces a full
inhibition of HER1 phosphorylation. Figure 6 gives a graphic
synopsis of these findings. To our knowledge, there are no other
studies showing that CXCL12 can transinhibit the phosphoryla-
tion of HER1 through intracytoplasmic pathways in CXCR4/
HER1 double-positive cells.
Stimulation with CXCL12 led to 2 events: 1) activation of
calmodulin/calcineurin and 2) transinhibition of tyrosine phos-
phorylation at the cytoplasmic tail of HER1. Prestimulation of
Figure 5. Regulation of HER1 Y1068 or Y1173 phosphorylation downstream of G-proteins requires calmodulin/calcineurin activity.
(A) and (B) Time-course. HeLa cells were stimulated as indicated in Figure 3. Treatment with W-13 (a calmodulin inhibitor) or CsA (a calcineurin
inhibitor) restored HB-EGF-dependent HER1 phosphorylation at Y1068, whereas KN-62 (a CaMKII inhibitor) had no effect. (C) Following prestimulation
with [N33A]CXCL12 the HB-EGF-dependent HER1 phosphorylation at Y1068 and Y1173 was abolished at the plateau (15 minutes) and restored by W-
13 or CsA; KN-62 had no effect. The means 6SD of 10 experiments are depicted.
doi:10.1371/journal.pone.0034432.g005
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dependent HER1 stimulation by delaying peak phosphorylation at
tyrosine 1068 and 1173. This effect was ultimately mediated by the
Ca
2+-calmodulin-activated protein phosphatase calcineurin, be-
cause PKC, calmodulin or calcineurin, but not CaMKII,
inhibition could abolish the delay of the HER1 phosphorylation.
All this did not affect CXCR4 internalization or CXCL12-
dependent chemotaxis. Therefore the CXCL12-dependent inhib-
itory effect on HER1 was genuine, specific and associated with a
G-protein/calmodulin/calcineurin-dependent transduction path-
way. The variant [N33A]CXCL12 [28] induced CXCR4
internalization and chemotaxis in a manner similar to recombi-
nant CXCL12 [32], but it abolished the HB-EGF-dependent
Y1068 and Y1173 phosphorylation of HER1. It turned out that
the variant CXCL12 acted as a G-protein-biased ligand for
CXCR4, lacking the capability of activating b-arrestin-dependent
ERK1/2 phosphorylation. Some [N33A]CXCL12-induced activ-
ities similar to recombinant CXCL12 may thus depend on p38
phosphorylation [33]. With both recombinant and variant forms,
HER1 phosphorylation was restored by inhibiting PKC or
calmodulin or calcineurin Though caution has been suggested
when interpreting the effects obtained with calmodulin inhibitors
in living cells, our results suggest in terms of exactly sequencial
timing that it is the lack of b-arrestin ERK1/2 signaling that does
maintain the inhibition of HER1 phosphorylation induced by
[N33A]CXCL12. In other words, b-arrestin activation seems to
revert HER1 transinhibition. We confirmed this in cells
knockdown of b-arrestin in which recombinant CXCL12 led to
full inhibition of HER1 as the mutant [N33A]CXCL12 did in
non-silenced cells.
We demonstrate that in two different human neoplastic cell
lines. But other studies provide circumstantial evidence that
support and expand our findings, which are in line with
experimental data regarding the effect of W-13 on HER1
activation [34], the global phosphorylation analysis downstream
of b-arrestin [14], and b-arrestin-mediated HER1 transactivation
[35]. Furthermore, in studying the CXCL12-induced phospho-
proteome adjustments in Hodgkin’s lymphoma-derived L540 cells,
which do not express HER1 but other HER receptors, we found
that HER2 phosphorylation is strongly downregulated 20 minutes
after stimulation with CXCL12.
The CXCL12-mediated, calcineurin-dependent modulation of
HER1 phosphorylation and the differential activity of recombi-
nant and mutated molecules should be seen in the context of
CXCR4 signaling specificity [36], [37]. In our experiments,
activation of a receptor led to different biological effects depending
on a single amino acid mutation in the ligand. The mutated amino
acid was outside of the receptor binding domains, which shows
that the ligand conformation provides a level of regulation for
signaling specificity, in terms of biased agonism. In the present
case, the biased agonist activated G-protein-dependent but not b-
arrestin-dependent pathways and it was capable of exerting a full
inhibitory effect on HER1 phosphorylation. This means that
[N33A]CXCL12 influenced specifically both the magnitude and
persistence of the cytokine signal as opposed to recombinant
CXCL12, thus leading to differentially regulated cellular activities.
In general, this conformation-related, magnitude- and persistence-
dependent signaling should be evaluated in terms of cytokine
networks that in turn either generate or diminish the specificity of
a given signal [3], [38]. It may also have played a role in
evolutionary terms [39], and we can envisage diseases arising from
acquired or congenital variations of chemokine/receptor structure
conditioning biased responses, as well as selective chemokine-
derived drugs [17], [18]. Because there is at least one structural
variant of CXCL12 that inhibits HER1 phosphorylation, it follows
that we have devised a strategy in which CXCL12 variants may be
Figure 6. CXCL12 and [N33A]CXCL12 transinhibit HER1 in 5637 or HeLa cells. Both chemokines signal via G-proteins to calmodulin/
calcineurin and modulate the ligand-dependent phosphorylation of HER1. CXCL12 induces a delay in the phosphorylation. [N33A]CXCL12, which is a
G-protein-biased ligand, inhibits the HER1 phosphorylation.
doi:10.1371/journal.pone.0034432.g006
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signaling. This in turn raises the question as to whether this may
encompass a possible approach to control unwarranted prolifer-
ation via engineered CXCL12 with inhibitory capabilities.
The modulation of HER1 phosphorylation may play a role in
cellular responses characteristic of invasive growth. This can be
thought of as a behavioral program that regulates cell dissociation
from its microenvironment, thus promoting cell migration and the
colonization of new sites. This program is shared by normal cells
involved in developmental, inflammatory or immune tasks and
cancer cells in the metastatic process. Based on the findings in the
present and other works [40], [41], [42], the crosstalk between
CXCL12 and HERs adds a new layer to HERs regulation that
may be involved in shifting cells alternatively toward differentia-
tion (HER1 transinhibition) or self-renewal (HER1 transactiva-
tion). In addition to its direct action on neoplastic cells, CXCL12
has emerged as a monocyte-macrophage regulator in the context
of the M2-polarized inflammatory responses [5]. M2-polarized
tumor-associated macrophages may promote tumor cell prolifer-
ation under CXCL12 stimulation [5], [8]. Eventually this links
inflammation to proliferation/differentiation and to oncogenes
[8], [43], [44], [45], [46], [47]. Therefore, structural variants that
transinhibit HER receptors should be tested to downregulate the
mitogenic potential of CXCR4/HER double-positive neoplastic
cells, to redirect the activity of CXCL12 on monocytes/
macrophages and to potentiate M1 responses. This should be a
more conservative and subtle approach as opposed to the use of
CXCR4 inhibitors.
In conclusion, this work provides new evidence that the
signaling mediated by CXCL12 via CXCR4 is capable of
activating an inhibitory calmodulin/calcineurin module that
modifies the magnitude and persistence of HER1 signaling. Taken
together, these data contribute a refinement to our understanding
of the signaling downstream of CXCR4 and HER1 [48]. This
hints at a unifying concept for explaining the significance of the
CXCL12/HER1 crosstalk in physiology and pathology dependent
on the balance between transinhibition and transactivation, while
suggesting at the same time a variety of potentially selective
therapeutic tools in a number of reactive or neoplastic conditions.
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